Trubion Pharmaceuticals Inc. Files For Initial Public Offering
Morgan Stanley & Co. Incorporated is acting as the sole book running and joint lead manager for the offering. Banc of America Securities LLC is acting as co-lead manager for the offering. Co-managers for the offering are Pacific Growth Equities, LLC and Lazard Capital Markets. The number of shares to be offered and the price range for the offering have not yet been determined. When available, preliminary prospectuses may be obtained from Morgan Stanley's prospectus department at 180 Varick, New York, NY 10014, by telephone at 866-718-1649 or by emailing prospectus@morganstanley.com.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Trubion
Trubion is a biopharmaceutical company developing a pipeline of product candidates to treat autoimmune disease and cancer. The company utilizes its Small Modular ImmunoPharmaceutical (SMIP(TM)) custom drug assembly technology to develop single-chain polypeptides that it believes offer the potential for safer and more effective therapies than products currently marketed or in late-stage clinical trials.
Contact: Michelle Burris SVP, Chief Financial Officer Trubion Pharmaceuticals, Inc. 206-838-0500
Source: Trubion Pharmaceuticals, Inc.